Path: utzoo!utgpu!watmath!uunet!bionet!nihcu.bitnet!CZJ From: CZJ@nihcu.bitnet Newsgroups: bionet.sci-resources Subject: (none) Message-ID: <8812182021.AA10416@net.bio.net> Date: 15 Dec 88 23:35:20 GMT Sender: daemon@NET.BIO.NET Lines: 215 Attached is the Table of Contents and articles of Interest from the NIH Guide to Grants and Contracts 12/16/88 Jim Cassatt |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Vol. 17, No. 42, December 16, 1988 DATED ANNOUNCEMENTS (RFPs AND RFAs) IMMUNOLOGICAL AND BIOLOGICAL CONSEQUENCES OF GENETIC VARIATION OF HIV AND RELATED IMMUNODEFICIENCY VIRUSES (RFP) ............(84/119)......... 1 National Institute of Allergy and Infectious Diseases Index: ALLERGY, INFECTIOUS DISEASES PURIFICATION, ISOLATION, AND CHARACTERIZATION OF GONADAL POLYPEPTIDES (RFP) ........................................(122/165)........ 1 National Institute of Child Health and Human Development Index: CHILD HEALTH, HUMAN DEVELOPMENT PATHOGENESIS AND NATURAL HISTORY OF HUMAN PAPILLOMA VIRUSES ..(168/260)..... 2 National Institute of Allergy and Infectious Diseases (912/1187) Index: ALLERGY, INFECTIOUS DISEASES MODELS FOR TREATING HIGH BLOOD CHOLESTEROL (RFA) ............(263/300)...... 3 National Heart, Lung, and Blood Institute Index: HEART, LUNG, BLOOD DEVELOPMENT OF THE SIMIAN IMMUNODEFICIENCY VIRUS (SIV) MODEL FOR AIDS VACCINE STUDIES (RFA) .......................(303/347, 1186/1640).. 3 National Institute of Allergy and Infectious Diseases Index: ALLERGY, INFECTIOUS DISEASES CLINICAL STUDIES OF SAFETY AND EFFECTIVENESS OF ORPHAN PRODUCTS (RFA) ........................................(350/435, 1643/2142). 4 Food and Drug Administration Index: FOOD AND DRUG ADMINISTRATION IMPROVED METHODS FOR THE EARLY DIAGNOSIS OF HIV-INFECTION IN NEONATES, INFANTS, AND CHILDREN (RFA) ...............(438/483, 2145/2392).... 5 National Institute of Child Health and Human Development Index: CHILD HEALTH, HUMAN DEVELOPMENT ONGOING PROGRAM ANNOUNCEMENTS RESEARCH IN PAGET'S DISEASE OF BONE ........................(489/629)....... 6 National Institute of Arthritis and Musculoskeletal and Skin Diseases Index: ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES POSTDOCTORAL FELLOWSHIPS FOR TRAINING IN REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY ...................................(632/739)....... 8 National Institute of Environmental Health Sciences Index: ENVIRONMENTAL HEALTH SCIENCES IMPACT OF ENVIRONMENTAL AGENTS ON REPRODUCTIVE PROCESSES ...(742/838)....... 9 National Institute of Environmental Health Sciences Index: ENVIRONMENTAL HEALTH SCIENCES DATED ANNOUNCEMENTS (RFPs AND RFAs) IMMUNOLOGICAL AND BIOLOGICAL CONSEQUENCES OF GENETIC VARIATION OF HIV AND RELATED IMMUNODEFICIENCY VIRUSES RFP AVAILABLE: RFP-NIH-NIAID-AIDSP-89-5 P.T. 34; K.W. 0715008, 0715120, 1002045, 0710070 National Institute of Allergy and Infectious Diseases The Vaccine Research and Development Branch, AIDS Program, NIAIDD, NIH, has a requirement for contractors to immunologically and biologically characterize at least five, and up to ten, virus strains derived from molecularly cloned HIV and related immunodeficiency viral genomes. This NIAID-sponsored project will take approximately five (5) years to complete. A cost reimbursement contract is anticipated. It is anticipated that two (2) awards will be made. This is an announcement for an anticipated Request for Proposal (RFP). RFP-NIH-NIAID-AIDSP-89-5 will be issued on or about December 15, 1988, with a closing date tentatively set for February 2, 1989. Requests for the RFP should be directed in writing to: Ms. Ann Linkins Contract Management Branch Westwood Building, 5333 Westbard Avenue, Room 707 National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, Maryland 20892 To receive a copy of the RFP, please supply this office with two (2) self-addressed mailing labels. All responsible sources may submit a proposal which will be considered. This advertisement does not commit the Government to award a contract. PURIFICATION, ISOLATION, AND CHARACTERIZATION OF GONADAL POLYPEPTIDES RFP AVAILABLE: NICHD-CD-89-10 P.T. 34; K.W. 0760060, 1003002, 1003008 National Institute of Child Health and Human Development The Contraceptive Development branch of the Center for Population Research, National Institute of Child Health and Human Development, has a requirement for the purification, isolation, and characterization of new gonadal polypeptides which play a role in the regulation of reproductive functions. The goal of this contract program is the structural elucidation of these gonadal polypeptides. Partially purified material(s) will made available for biological evaluation (after independent verification of the biological activity) and will be distributed to the scientific community. It is anticipated that three awards be made under the RFP for a period of three years, each. Offerors will be required to propose the gonadal polypeptide factor(s) to be pursued. The isolation of the factor(s) to be pursued will be limited to those present in porcine follicular fluid (pFF). Offerors are not required to have, in-house, all of the capabilities to purify, isolate, biologically characterize and chemically characterize (including primary structure determination) the proposed factors. Documented collaboration under a subcontract is encouraged but the prime contractor must be able to conduct, in-house, the necessary biological assays to follow the activity of the factor(s) proposed for purification and isolation. The biological collaboration will also allow for the broader aspects of identifying other potentially important factor(s) in pFF. This is not a Request for Proposals. The RFP will be issued on or about December 23, 1988 with a due date approximately 90 days thereafter. Copies of the RFP may be obtained by sending written requests to the following address. Please enclose a self-addressed label. Vol. 17, No. 42, December 16, 1988 - Page 1 Paul J. Duska, Contracting Officer Contracts Management Section, OGC National Institute of Child Health and Human Development Executive Plaza North, Room 610 Bethesda, Maryland 20892 DEVELOPMENT OF THE SIMIAN IMMUNODEFICIENCY VIRUS (SIV) MODEL FOR AIDS VACCINE STUDIES RFA AVAILABLE: 89-AI-01 P.T. 34; K.W. 0715120, 1002045, 0740075, 0715008, 0710070 National Institute of Allergy and Infectious Diseases RFA Availability Date: Immediately Letter of Intent Date: February 1, 1989 Application Receipt Date: April 4, 1989 The National Institute of Allergy and Infectious Diseases (NIAID) announces the availability of an RFA for funding Development of the SIV Model for AIDS Vaccine Studies. This RFA (available on request) invites applications aimed Vol. 17, No. 42, December 16, 1988 - Page 3 at systematic evaluations of virologic and immunologic aspects of SIV infection and their relevance in AIDS vaccine development. Scientific approaches including defining the extent and immunologic consequences of viral genetic variation during infection, determining immunologic correlates of immunity and surrogate markers for disease progression, and characterizing and standardizing assays for humoral and cellular immune responses to vaccines and infection are encouraged. Awards will be made as Cooperative Agreements. Assistance by this mechanism differs from the usual research grant in that the Government component (in this instance, NIAID) awarding the Cooperative Agreement anticipates substantial involvement during performance. The nature of NIAID staff participation is described in the RFA. The applicant, however, must define his/her research interests and goals and is responsible for conducting the research supported by the grant. Investigators from any institution, foreign or domestic, are eligible to apply for this funding. This RFA is available from the following: Dr. Alan M. Schultz NIAID, AIDS Program Vaccine Research and Development Branch 6003 Executive Blvd., Room 236P Rockville, Maryland 20892 Telephone: (301) 496-8200